NICM
CELG

Neo Ivy Capital Management’s Celgene Corp CELG Stock Holding History

Neo Ivy Capital Management’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6,385
Closed -$409K – 431
2018
Q4 		$409K Buy
+6,385
New +$471K 0.32% 139

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Neo Ivy Capital Management's CELG Position: Q1 2019 in Review

Neo Ivy Capital Management sold out of Celgene Corp (CELG) in Q1 2019, closing a stake of 6,385 shares — an estimated $409K sold.

Neo Ivy Capital Management first reported a position in CELG in Q4 2018 and held it in 1 quarter. The position peaked at $409K in Q4 2018. 1,389 funds tracked by Wall St. Rank hold CELG as of Q1 2019.

  • Neo Ivy Capital Management reported no remaining Celgene Corp position as of Q1 2019 after selling out during the quarter.
  • Neo Ivy Capital Management sold 6,385 Celgene Corp shares in Q1 2019, an estimated $409K.
  • Neo Ivy Capital Management first reported a position in Celgene Corp in Q4 2018 and held it in 1 quarter.
  • Neo Ivy Capital Management's Celgene Corp position peaked at $409K in Q4 2018.
  • 1,389 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2019.

Based on Neo Ivy Capital Management's 13F filing for Q1 2019, filed 15 May 2019.